Orthopedic Surgery Doctors in Lehighton, PA Accepting Medicare

5 Orthopedic Surgery doctors found. Showing 1 - 5

Dr. Eric Michael Pridgen, MD Orthopaedic Surgery - Sports Medicine Medicare: Medicare Enrolled Practice Location: 575 S 9th St Ste 5, Lehighton, PA 18235 Phone: 484-526-1735

Daniel E. Muser, M.D. Orthopaedic Surgery Medicare: Not Enrolled in Medicare Practice Location: 246 N 6th St, Lehighton, PA 18235 Phone: 610-377-2224    Fax: 610-377-6484

Robert B. Grob, D.O. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 246 N 6th St, Lehighton, PA 18235 Phone: 610-377-2224    Fax: 610-377-6484

Emma Fink, PA-C Orthopaedic Surgery - Sports Medicine Medicare: Medicare Enrolled Practice Location: 211 N 12th St, Lehighton, PA 18235 Phone: 866-785-8537

Dr. Jon David Hernandez, M.D. Orthopaedic Surgery Medicare: Accepting Medicare Assignments Practice Location: 2226 Blakeslee Boulevard Dr E Ste 200, Lehighton, PA 18235 Phone: 610-408-8900

News Archive

Cortex signs agreement to sell certain AMPAKINE compounds to Biovail

Cortex Pharmaceuticals, Inc. announced that it has entered into an agreement with Biovail Laboratories International SRL in which Biovail acquired certain AMPAKINE compounds and the rights to the patent filing for respiratory depression and vaso-occlusive crises associated with sickle cell disease.

Promising new therapeutic strategy for chronic kidney disease

Chronic kidney disease (CKD) affects at least one in four Americans who are older than 60 and can significantly shorten lifespan. Yet the few available drugs for CKD can only modestly delay the disease's progress towards kidney failure. Now, however, a team led by researchers at the Perelman School of Medicine at the University of Pennsylvania, has found an aspect of CKD's development that points to a promising new therapeutic strategy.

Research Roundup: Raising Medicare's eligibility age; Insurance status affects ER imaging services

Raising The Ages Of Eligibility For Medicare And Social Security - The authors analyzed a scenario in which the eligibility age - current 65 - would be increased by two months every year until it reached 67 in 2027. They found that would cut Medicare expenditures by 5 percent but many people between the ages of 65 and 67 would pay more for health care.

Hanwha, Merck partner to develop and commercialize HD203

Merck, known as MSD outside the United States and Canada, and Hanwha Chemical Corporation today announced that they have entered into an exclusive global agreement to develop and commercialize a candidate biosimilar form of Enbrel.

Read more Medical News

› Verified 8 days ago